SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients

Translational Oncology

Volumn 2, Issue 2, 2009, Pages 59-64

  Desai, Neil ^a   Trieu, Vuong ^a   Damascelli, Bruno ^b   Soon Shiong, Patrick ^a  

^a Abraxis BioScience LLC   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; OSTEONECTIN; PACLITAXEL;

ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; ETHMOID SINUS; GENE OVEREXPRESSION; GINGIVA TUMOR; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; JAW TUMOR; LARYNX TUMOR; LIP TUMOR; MAJOR CLINICAL STUDY; MONOTHERAPY; NASOPHARYNX TUMOR; NOSE TUMOR; OROPHARYNX TUMOR; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; RETROSPECTIVE STUDY; SOLID TUMOR; SURVIVAL TIME; TONGUE TUMOR; TONSIL TUMOR; TUMOR BIOPSY; TUMOR CLASSIFICATION; UPREGULATION;

EID: 70350134980     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.09109     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008). Cancer statistics, 2008. CA Cancer J Clin 58, 71-96.
2. Robbins KT, Storniolo AM, Kerber C, Vicario D, Seagren S, Shea M, Hanchett C, Los G, and Howell SB (1994). Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol 12, 2113-2120.
3. Damascelli B, Cantu G, Mattavelli F, Tamplenizza P, Bidoli P, Leo E, Dosio F, Cerrotta AM, Di Tolla G, Frigerio LF, et al. (2001). Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer 92, 2592-2602.
4. Damascelli B, Patelli G, Ticha V, Di Tolla G, Frigerio LF, Garbagnati F, Lanocita R, Marchiano A, Spreafico C, Mattavelli F, et al. (2007). Feasibility and efficacy of percutaneous transcatheter intraarterial chemotherapy with paclitaxel in albumin nanoparticles for advanced squamous-cell carcinoma of the oral cavity, oropharynx, and hypopharynx. J Vasc Interv Radiol 18, 1395-1403.
5. Damascelli B, Patelli GL, Lanocita R, Di Tolla G, Frigerio LF, Marchiano A, Garbagnati F, Spreafico C, Ticha V, Gladin CR, et al. (2003). A novel intra-arterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings. AJR Am J Roentgenol 181, 253-260.
6. Trieu V, Hwang J, and Desai N (2007). Nanoparticle Albumin-bound (nab) technology may enhance antitumor activity via targeting of SPARC protein. In: New Targets and Delivery System for Cancer Diagnosis and Treatment (SKCC), San Diego, CA. Abstract 53.
7. Sage H, Johnson C, and Bornstein P (1984). Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. J Biol Chem 259, 3993-4007.
8. Brekken RA and Sage EH (2001). SPARC, a matricellular protein: at the cross-roads of cell-matrix communication. Matrix Biol 19, 816-827.
9. Porter PL, Sage EH, Lane TF, Funk SE, and Gown AM (1995). Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem 43, 791-800.
10. Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, and Llera AS (2008). The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 27, 523-537.
11. Koukourakis MI, Giatromanolaki A, Brekken RA, Sivridis E, Gatter KC, Harris AL, and Sage EH (2003). Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 63, 5376-5380.
12. Chin D, Boyle GM, Williams RM, Ferguson K, Pandeya N, Pedley J, Campbell CM, Theile DR, Parsons PG, and Coman WB (2005). Novel markers for poor prognosis in head and neck cancer. Int J Cancer 113, 789-797.
13. Kato Y, Nagashima Y, Baba Y, Kawano T, Furukawa M, Kubota A, Yanoma S, Imagawa-Ishiguro Y, Satake K, Taguchi T, et al. (2005). Expression of SPARC in tongue carcinoma of stage II is associated with poor prognosis: an immunohistochemical study of 86 cases. Int J Mol Med 16, 263-268.
14. Stehle G, Sinn H, Wunder A, Schrenk HH, Stewart JC, Hartung G, Maier-Borst W, and Heene DL (1997). Plasma protein (albumin) catabolism by the tumor itself - implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol 26, 77-100.
15. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, and O'Shaughnessy J (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23, 7794-7803.
16. Trieu VN, Narla RK, Myers DE, and Uckun FM (2000). EGF-genistein inhibits neointimal hyperplasia after vascular injury in an experimental restenosis model. J Cardiovasc Pharmacol 35, 595-605.
17. Gradishar WJ (2006). Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7, 1041-1053.
18. Borad M, Penny R, Bittner M, Gardiner J, Shack S, Campbell E, Taverna D, Love R, Trent J, and Von Hoff DD (2006). Molecular profiling using immunohistochemistry (IHC) and DNA microarray (DMA) as a tool to determine potential therapeutic targets in patients who have progressed on multiple prior therapies. In: First AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Chicago, IL. Abstract B82.
19. Trieu V, Frankel T, Labao E, Soon-Shiong P, and Desai N (2005). SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol. In: American Association for Cancer Research (AACR) Annual Meeting, Anaheim, CA. Abstract 5584.
20. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, et al. (2006). Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res 12, 1317-1324.
21. Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, and Gradishar WJ (2008). Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 19, 899-909.
22. Von Hoff DD, Borad M, Ramanathan RK, Smith LS, Drengler RL, Wood TE, Laheru D, and Hidalgo M (2008). Promising clinical activity of a NAB paclitaxel plus gemcitabine combination in a disease-specific phase I in patients with advanced pancreatic cancer. In: American Association for Cancer Research (AACR) Annual Meeting, San Diego, CA. Abstract 4179.